ライフサイエンスコーパス: rifaximin

1 to study the efficacy and safety profile of rifaximin.

2 at treatment with the nonsystemic antibiotic rifaximin.

3 ,011 dynes x s/cm(5) ) revealed no effect of rifaximin.

4 S symptoms with antibiotic therapy including rifaximin.

5 with that of vancomycin, metronidazole, and rifaximin.

6 d pharmacologic treatment with lactulose and rifaximin.

7 es in patients with MHE after treatment with rifaximin.

8 bo, over a 6-month period (hazard ratio with rifaximin, 0.42; 95% confidence interval [CI], 0.28 to 0

9 < 0.01) and receiving antibiotics other than rifaximin (10.5 days; p < 0.01) were associated with lon

10 ons), levofloxacin (500 mg; 111 persons), or rifaximin (1650 mg; 107 persons), in combination with lo

11 emission then began maintenance therapy with rifaximin 200 mg/day (to 1800 mg/day) for up to 24 month

12 uadalajara, Mexico, 210 U.S. adults received rifaximin (200 mg/d, 200 mg twice daily, or 200 mg 3 tim

13 were randomly assigned to receive 400 mg of rifaximin 3 times daily for 10 days (n = 43) or placebo

14 patients (44.1%) who responded to open-label rifaximin, 382 (35.6%) did not relapse and 692 (64.4%) d

15 romycin, 3.8 hours; levofloxacin, 6.4 hours; rifaximin, 5.6 hours).

16 responding to a 2-week course of open-label rifaximin 550 mg 3 times daily, who then relapsed during

17 ssigned to groups given repeat treatments of rifaximin 550 mg or placebo 3 times daily for 2 weeks.

18 le outpatients with cirrhosis and ascites to rifaximin 550 mg twice a day (n = 36) or placebo twice a

19 Of patients given rifaximin, 91% improved their cognitive performance, com

20 We evaluated rifaximin, a minimally absorbed antibiotic, as treatment

21 The efficacy of rifaximin, a minimally absorbed antibiotic, is well docu

22 discuss the potential mechanism of action of rifaximin, a minimally absorbed antibiotic.

23 Rifaximin, a nonabsorbable antibiotic that decreases lip

24 The efficacy of rifaximin, a nonabsorbed antimicrobial agent, was demons

25 rated by an improved synthetic strategy, and rifaximin, a potent PXR agonist, demonstrated that conic

26 Oral rifaximin altered the composition of bacterial communiti

27 estraint stressors, and investigated whether rifaximin altered the gut microbiota, prevented intestin

28 Rifaximin alters the bacterial population in the ileum o

29 Rifaximin, an oral, non-systemic, broad-spectrum antibio

30 a developed in 14.74% of participants taking rifaximin and 53.70% of those taking placebo (rate ratio

31 has been an increased interest in the use of rifaximin and albumin in various settings of ArLD.

32 cted mucosal breaks in 20% of subjects given rifaximin and in 43% of subjects given placebo (P = .05

33 tes of adverse events were comparable in the rifaximin and placebo groups.

34 e azithromycin, effectiveness of single-dose rifaximin, and emerging resistance to front-line agents

35 Both FDX and OP-1118 (unlike vancomycin, rifaximin, and metronidazole) effectively inhibited spor

36 Rifaximin appears promising as a chemoprophylaxis for tr

37 Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapie

38 there were no significant changes within the rifaximin arm.

39 e there was no significant change within the rifaximin arm.

40 and 1.9% in azithromycin, levofloxacin, and rifaximin arms, respectively) (P = .55).

41 74.8% of the levofloxacin, azithromycin, and rifaximin arms, respectively.

42 Patients' response to rifaximin as a maintenance therapy appears to be favorab

43 onstipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times da

44 Among patients not on rifaximin at enrollment, GPB reduced the proportion of p

45 In contrast, vancomycin, metronidazole, and rifaximin (at similar sub-MICs) did not inhibit sporulat

46 from chronic liver disease to receive either rifaximin, at a dose of 550 mg twice daily (140 patients

47 study is needed in Asia to determine whether rifaximin can prevent diarrhea caused by invasive bacter

48 g simulator performance after treatment with rifaximin, compared with placebo.

49 mics in patients with cirrhosis and ascites; rifaximin did not affect glomerular filtration rate or l

50 Four weeks of treatment with rifaximin did not reduce the hepatic venous pressure gra

51 , respectively (P < 0.001 for both), and all rifaximin doses were superior to placebo.

52 us omeprazole (20 mg once daily), and either rifaximin-EIR (400 mg) or placebo, twice daily for 14 da

53 f patients who received the 800-mg dosage of rifaximin-EIR (61 of 98) were in remission, compared wit

54 ients given the 400-mg and 800-mg dosages of rifaximin-EIR had low rates of withdrawal from the study

55 Administration of 800 mg rifaximin-EIR twice daily for 12 weeks induced remission

56 Data from patients given rifaximin-EIR were compared with those from individuals

57 efficacy and safety of 400, 800, and 1200 mg rifaximin-EIR, given twice daily to 402 patients with mo

58 ents given the 400-mg and 1200-mg dosages of rifaximin-EIR, respectively; these rates did not differ

59 ine whether a gastroresistant formulation of rifaximin (extended intestinal release [EIR]) induced re

60 er a delayed-release antibiotic formulation (rifaximin-extended intestinal release [EIR]) prevents th

61 had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS

62 dence in the literature regarding the use of rifaximin for different gastrointestinal disorders.

63 None of the subjects in the rifaximin group developed large lesions, compared with 9

64 A total of 13.6% of the patients in the rifaximin group had a hospitalization involving hepatic

65 addition, significantly more patients in the rifaximin group had a response to treatment as assessed

66 ge-liver disease scores, but patients in the rifaximin group had increased levels of the anti-inflamm

67 Significantly more patients in the rifaximin group than in the placebo group had adequate r

68 Similarly, more patients in the rifaximin group than in the placebo group had adequate r

69 lopathy occurred in 22.1% of patients in the rifaximin group, as compared with 45.9% of patients in t

70 drivers were randomly assigned to placebo or rifaximin groups and followed up for 8 weeks (n = 42).

71 Rifaximin had no effect on hepatic venous pressure gradi

72 Rifaximin has been shown to be of benefit to these patie

73 ative options to standard therapies, whereas rifaximin has demonstrated success in uncontrolled trial

74 f fusidic acid and bacitracin and, possibly, rifaximin if resistance to this agent becomes widespread

75 Rifaximin improves IBS symptoms for up to 10 weeks after

76 nvestigated the efficacy and tolerability of rifaximin in maintaining symptomatic and endoscopic remi

77 Rifaximin is a gastrointestinal-selective antibiotic wit

78 Rifaximin is a poorly absorbed antimicrobial with activi

79 Rifaximin is currently approved in the United States for

80 Rifaximin is effective for the treatment of travelers' d

81 Future studies should evaluate whether rifaximin is effective in preventing postinfectious irri

82 Rifaximin is gaining attention for its potential activit

83 Rifaximin is increasingly important as a therapy for hos

84 Rifaximin is used to treat patients with functional gast

85 Over the 8-week study period, patients given rifaximin made significantly greater improvements than t

86 Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopat

87 Intestinal decontamination with rifaximin may improve hemodynamics.

88 -one patients began maintenance therapy with rifaximin (median dose 200 mg/day); 33 (65%) maintained

89 In immune nonresponders to ART, rifaximin minimally affected microbial translocation and

90 We propose that rifaximin modulates the ileal bacterial community, reduc

91 ly assigned to receive repeat treatment with rifaximin (n = 328) or placebo (n = 308).

92 Compared with no study treatment (n = 22), rifaximin (n = 43) use was associated with a significant

93 controlled trial investigates the effects of rifaximin on hemodynamics, renal function, and vasoactiv

94 ering therapy by l-ornithine l-aspartate and rifaximin orally for 4 weeks.

95 Noninferiority could not be shown with rifaximin (P = .07).

96 Rifaximin prevents travelers' diarrhea with minimal chan

97 Rifaximin provided 72% and 77% protection against travel

98 score, gender, use of antibiotics other than rifaximin, reason for admission and hepatitis C are pred

99 In addition, rifaximin recipients had a lower bloating score after tr

100 Over the 10 weeks of follow-up, rifaximin resulted in greater improvement in IBS symptom

101 Rifaximin safely prevented travelers' diarrhea in Mexico

102 ups that did not report travelers' diarrhea, rifaximin significantly reduced the occurrence of mild d

103 Rifaximin significantly reduced the risk of an episode o

104 of responders was significantly greater with rifaximin than placebo (38.1% vs 31.5%; P = .03).

105 2%; P = .018) was significantly greater with rifaximin than placebo, but not stool consistency (51.8%

106 Eighty participants completed rifaximin therapy or placebo, and follow-up data were av

107 Rifaximin therapy was not cost-saving at current prices

108 changes in coliform flora were found during rifaximin therapy.

109 hronic pouchitis, studies found success with rifaximin, tinidazole, and oral budesonide.

110 Rifaximin treatment also significantly reduced the risk

111 cacy and safety data from clinical trials of rifaximin treatment of IBS.

112 nts with relapsing symptoms of IBS-D, repeat rifaximin treatment was efficacious and well tolerated.

113 score, serum sodium, albumin, lactulose use, rifaximin use, and benzodiazepine/barbiturate sedation.

114 significant bacterial resistance will limit rifaximin use.

115 unts <350 cells/mm(3) were randomized 2:1 to rifaximin versus no study treatment for 4 weeks.

116 )T-cell activation (median change, 0.0% with rifaximin vs +0.6% with no treatment; P = .03).

117 Rifaximin was found to be safe and well tolerated in lon

118 Rifaximin was found to lead to better maintenance of rem

119 Rifaximin was found to lead to better maintenance of rem

120 Although rifaximin was slightly more effective than lactulose in

121 ent of irritable bowel syndrome-diarrhoea is rifaximin, which was approved in May 2015.

122 Treatments considered were lactulose or rifaximin, which were assumed to reduce the MVA rate to

123 with cirrhosis, including 59 already taking rifaximin, who had experienced two or more hepatic encep

124 Single-dose azithromycin, levofloxacin, and rifaximin with loperamide were comparable for treatment